Alli Return In U.S. Fattens Glaxo’s Consumer Outlook
This article was originally published in The Tan Sheet
Executive Summary
GSK Consumer Healthcare says alli would be available starting Feb. 25 in most stores in the U.S. and Puerto Rico in “improved tamper-evident packaging.” Despite the product’s checkered history, its return marks another boost for Glaxo’s consumer outlook.
You may also be interested in...
Alli Recall Could Help Mitigate Reputation Damage In Face Of Tampering
GSK investigates tampering with its alli weight-loss drug and positions itself as a consumer advocate with a U.S. recall of the product. By showing it is “on the side of good” the firm could actually emerge from the crisis with a stronger reputation, says crisis management expert Gene Grabowski says.
Glaxo Keeps Alli As Recently Pruned Consumer Division Thrives
GlaxoSmithKline abandons its attempt to divest the OTC weight loss aid alli, even though the beleaguered brand continues to drag down consumer division sales. The division’s sales climbed 7% excluding alli in the firm’s second quarter, but only 5% including the product’s results.
Alli Campaign Seeks To "Drive Behavior Change," Stresses Healthy Choices
GlaxoSmithKline's back-to-the-basics advertising for alli educates consumers about how the weight-loss drug works and the importance of healthy eating and exercise.